NovaBridge Biosciences (NBP) — Financial Flexibility Index

Latest as of September 2025: 0.10x

NovaBridge Biosciences (NBP) has a Financial Flexibility Index of 0.10x as of September 2025. Free cash flow of $13.15 Million (operating CF $13.15 Million minus capex $41.00) represents 0% of total liabilities ($131.67 Million). Also explore NovaBridge Biosciences net asset momentum to track the company's year-over-year net asset growth rate.

Financial Flexibility Index

0.10x
Free Cash Flow / Total Liabilities

Free Cash Flow

$13.15 Million
Operating CF − Capex

Total Liabilities

$131.67 Million
USD

Capital Expenditures

$41.00
USD

NovaBridge Biosciences Financial Flexibility Index (2017–2024)

Historical Financial Flexibility Index trend for NovaBridge Biosciences across 8 annual periods. Check NBP capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Annual Financial Flexibility Index for NovaBridge Biosciences (2017–2024)

Year-by-year free cash flow to debt coverage for NovaBridge Biosciences. For the full company profile including market capitalisation, see NovaBridge Biosciences (NBP) total market value.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2024 -4.57x $-52.60 Million $-52.65 Million $11.52 Million ▼ -5521.1%
2023 -0.08x $-72.69 Million $-72.85 Million $894.81 Million ▲ +91.8%
2022 -0.99x $-1.06 Billion $-1.10 Billion $1.07 Billion ▼ -9.6%
2021 -0.91x $-943.16 Million $-973.09 Million $1.04 Billion ▼ -244.9%
2020 0.62x $441.57 Million $433.56 Million $706.65 Million ▲ +375.5%
2019 -0.23x $-855.74 Million $-867.98 Million $3.77 Billion ▼ -183.8%
2018 -0.08x $-266.30 Million $-280.70 Million $3.33 Billion ▲ +54.3%
2017 -0.17x $-231.83 Million $-252.16 Million $1.33 Billion
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities